



PH -7064 NP #14

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paul D. Golian

Type or print name

Signature

December 18, 2002

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**IN THE APPLICATION OF:**

CARL P. DECICCO ET AL.

CASE NO.: PH-7064

APPLICATION NO.: 09/783,248

GROUP ART UNIT: 1624

FILED: FEBRUARY 14, 2001

EXAMINER: KIFLE, BRUCK

FOR: MATRIX METALLOPROTEINAE INHIBITORS AND USES THEREOF

**PRELIMINARY AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In response to the Notice to Comply dated October 7, 2002, please amend the application as follows and consider the following remarks.

IN THE SEQUENCE LISTING:

Please insert the enclosed Sequence Listing into the application.

IN THE SPECIFICATION:

Please replace the following paragraphs:

Paragraph beginning at page 125, line 36:

MCA peptide substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-NH₂ (SEQ ID NO:1). Peptide stocks are stored at -70 C in DMSO at 20 mM. Dilute peptide in 1 x reaction buffer to a working concentration of 14 uM on day of use.

Paragraph beginning at page 127, line 3:

MCA Peptide substrate: Mca-PLAQAV(Dpa)RSSSR-NH₂ (SEQ ID NO:2). Peptide stocks are stored at -70 C in DMSO at 20 mM. Dilute peptide stock in reaction buffer to a working concentration of 20 uM on day of use.

REMARKS

A Sequence Listing has been added in response to the Notice to Comply and the specification has been amended to refer to the Sequence Listing. A marked-up version of these amendments is found beginning on a separate sheet entitled "Version With Markings to Show Changes Made." No new matter is believed to be added.

Please charge any necessary fees or credit any overpayment to Deposit Account 19-3880 (Bristol-Myers Squibb Pharma Company).

In view of the foregoing, allowance of the above-referenced application is earnestly solicited.

Respectfully submitted,



Paul D. Golian
Attorney For Applicants
Registration No. 42,591
Telephone: (609) 252-4091

Dated: 12/18/02

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In showing the changes, deleted material is shown surrounded by brackets and added material is shown by underlining.

IN THE SPECIFICATION:

Paragraph beginning at page 125, line 36:

MCA peptide substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-NH₂ (SEQ ID NO:1). Peptide stocks are stored at -70 C in DMSO at 20 mM. Dilute peptide in 1 x reaction buffer to a working concentration of 14 uM on day of use.

Paragraph beginning at page 127, line 3:

MCA Peptide substrate: Mca-PLAQAV(Dpa)RSSSR-NH₂ (SEQ ID NO:2). Peptide stocks are stored at -70 C in DMSO at 20 mM. Dilute peptide stock in reaction buffer to a working concentration of 20 uM on day of use.